Full-Time

Access & Reimbursement Manager

Global Market Access & HEOR

Posted on 7/9/2025

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$158k - $205k/yr

Boston, MA, USA + 2 more

More locations: Providence, RI, USA | Hartford, CT, USA

Remote

Candidates must live in their territory or immediate adjacency.

Category
Sales & Account Management
Requirements
  • Bachelor’s degree in related field required. Equivalent combination of education and applicable job experience may be considered.
  • 5+ years in pharmaceutical / health industry working with Hubs, payers, HCPs or related area
  • 3+ years reimbursement / access / case management experience
  • Specialty pharmaceutical, nephrology, rare disease, REMs experience preferred.
Responsibilities
  • Serves as the key contact responsible for patient access and reimbursement in an assigned geography that provides appropriate support to providers and professional staff
  • Cultivate the highest level of expertise in the FILSPARI onboarding process, from Patient Start Form (PSF) submission through REMS enrollment to reimbursement
  • Walk offices through what to expect from the FILSPARI onboarding process, either when a new PSF comes in or when an opportunity for re-education is identified
  • Educate physicians and physician practices on the full FILSPARI onboarding process, including how to complete the PSF, how to enroll patients and physicians in REMS, requirements for prior authorization approvals, appeal approvals, and specific medical policy steps to obtain reimbursement
  • Closely monitor cases as they progress through the onboarding process
  • Proactively identify and solve complex patient access issues by working across the Hub, HCP offices and communicating with field team
  • Assist physicians and office staff when PSFs or REMS enrollment forms are submitted with information missing; coordinate with Hub and REMS Administrator partners to be able to clearly explain to the office what information is missing
  • Assist physicians and office staff in resolving access issues (prior authorization, appeals, denials, letters of medical necessity, REMS), and help ensure appropriate education to avoid future reimbursement hurdles
  • Effectively partner with reimbursement stakeholders (specialty pharmacy, sales team, HCP office, REMS administrator, etc.) to communicate challenges, identify solutions, and ensure the patient is progressing through the reimbursement process
  • Understand specifics and support questions associated with PSF submission, REMS enrollment, payer policies (e.g., PAs process and denial, and appeals), patient reimbursement (e.g., Co-pay, PAP), reimbursement issues & opportunities (as needed)
  • Proactively seek out timely and regular updates on case statuses, leveraging network of reimbursement stakeholders
  • Periodically ride with and educate sales force on complexities surrounding the pharmaceutical reimbursement process. Maintain a level of expertise on specific payors and the requirements for claim approvals
  • Log calls and notes within standardized platform daily, to provide clear and concise updates that drive toward action and emphasize next steps and owners (based on standardized template)
  • Lead weekly case status update meetings with sales force and sales leadership in a way that demonstrates confidence and preparedness and emphasizes specific next steps / owners
  • Coordinate with Hub, specialty pharmacies, and REMS administrator stakeholders to regularly share information and work together to move cases forward efficiently and smoothly
  • Balance daily tasks and schedule to accommodate ad-hoc communication from the sales force and sales leadership without delays to other ARM priorities
  • Operate in compliance with HIPAA within program guidelines
  • Deliver expertise in regional and local access landscape, anticipating changes in the healthcare landscape, and act as the Subject Matter Expert for FILSPARI onboarding, including reimbursement
  • Know your business to identify trending barriers to reimbursement within your geography, then create quarterly business plan to address these barriers
  • Bring forth opportunities / proposals for HCP office education, then work collaboratively with sales counterparts to develop and execute strategy
  • Work with market access team to monitor national and regional payer trends and changes, then educate both internal (sales) and external (HCPs) on changes
Desired Qualifications
  • The ideal candidate will embody Travere’s core values: Courage, Community Spirit, Patient Focus and Teamwork
  • Experience in managing access complexities associated with a new to market medication
  • Prior account management experience or prior experience with complex accounts (Payer landscape, government payer, VA)
  • Experience with specialty pharmacy products / products acquired through Specialty Pharmacy networks or specialty distributors (buy and bill)
  • Proven ability to build relationships with HCPs, office staff, sales team, and Hub counterparts
  • Comprehensive understanding of private/commercial insurance reimbursement, government payer Medicare Part D, VA, etc.
  • Demonstrated experience in helping to educate on reimbursement processes (inc. foundational knowledge of benefit verifications, prior authorization, appeals, denials, letters of medical necessity, pre-determination requirement
  • Computer skills (basic Excel, PowerPoint, etc.)
  • Ability to resolve issues / educate virtually (within access & reimbursement / case management)
  • Well organized with the ability to multitask, prioritize, and manage shifting responsibilities in a dynamic, cross-functional teamwork environment
  • Excellent collaboration skills with strong attention to detail and the ability to multi-task and manage complexity
  • Strong interpersonal and organizational skills and excellent verbal and written communication skills are required
  • The position is field based and the candidate must live in their territory or immediate adjacency
  • Flexibility to travel as needed (up to 35%)
  • The ability to perform face to face work with customers, colleagues and/or onsite in San Diego, and the ability to satisfactorily meet credentialing requirements for access to healthcare facilities and customer sites within your territory on an ongoing basis, are essential job functions of this position

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI Q1 2026 sales hit $105.2 million, up 88% year-over-year.
  • FSGS approval expands US addressable market beyond 100,000 patients.
  • Chugai submits sparsentan NDA in Japan 2026, triggering milestone payments.

What critics are saying

  • Robbins Geller investigates Travere for securities violations since January 2026.
  • Ligand claims 9% royalty on all worldwide FILSPARI sales.
  • Novartis atrasentan Phase III threatens 20-30% FILSPARI market share.

What makes Travere Therapeutics unique

  • FILSPARI is first FDA-approved therapy for FSGS in patients aged 8 and older.
  • FILSPARI leads IgAN market as most prescribed FDA-approved medicine.
  • Pegtibatinase advances as novel Phase 3 enzyme replacement for classical homocystinuria.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

INACTIVE